By Michele Gershberg (Reuters) – Powerful weight-loss medicines like Novo Nordisk’s Wegovy leapt into public view in 2023, from social media to doctors’ offices and cocktail parties, offering a new …
Weight-Loss
-
-
ZURICH (Reuters) – Nestle sees no threat to its huge coffee business from the rising popularity of weight-loss drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, Chief Executive Mark …
-
By Bhanvi Satija and Amruta Khandekar (Reuters) – Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock …
-
By Carolina Mandl NEW YORK (Reuters) – Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo …
-
By Maggie Fick and Bhanvi Satija (Reuters) – Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years – limited …
-
By Deborah Mary Sophia (Reuters) – Investors will look for signs that U.S. fast-food chains, already contending with inflation-stung consumers preferring to dine at home, will also have to grapple …
-
By Maggie Fick LONDON (Reuters) – Catalent’s plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk’s weight-loss drug Wegovy as part of the two companies’ expanded supply agreement, …
-
By Maggie Fick LONDON (Reuters) – Soaring U.S. demand for Novo Nordisk’s weight-loss drug has reduced the pressure from investors on the company to deliver strong results in its trial …
-
(Reuters) – The U.S. Food and Drug Administration (FDA) warned about the safety risks of using compounded or custom-made versions of popular weight-loss drugs such as Wegovy and diabetes drug …
-
By Jennifer Rigby DUBLIN (Reuters) – Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for …
-
By Ludwig Burger FRANKFURT (Reuters) – Zealand Pharma and partner Boehringer Ingelheim said their experimental obesity drug achieved up to 14.9% weight loss after 46 weeks in a mid-stage trial, …
-
By Patrick Wingrove (Reuters) – Novo Nordisk’s Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with …
-
By Bhanvi Satija (Reuters) – The American Academy of Pediatrics (AAP) on Monday recommended use of weight-loss drugs in children ages 12 years or older for treatment of obesity, which …
-
PHILADELPHIA – United States Attorney Jacqueline C. Romero announced that William Merlino, 85, of Mays Landing, NJ, was convicted at trial of selling misbranded drugs online, arising from his scheme …
-
CHICAGO — A federal judge in Chicago has sentenced a man to a year in prison for manufacturing and selling a purported weight-loss product containing the unapproved additive 2,4-Dinitrophenol, known …